Improved Early Diagnosis in Female Pelvic Cancer With OC Detect

Launched by REGION SKANE · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Improved Early Diagnosis in Female Pelvic Cancer With OC Detect," is studying whether a new tool can help doctors identify ovarian cancer earlier by looking at specific substances in the blood. These substances, known as Volatile Organic Compounds (VOCs), can show different patterns in women with ovarian cancer compared to those who are healthy. The trial aims to see if the OC Detect device can accurately tell the difference between these patterns in blood samples.

To participate in this study, you need to be a woman aged between 18 and 70 who either has been diagnosed with ovarian cancer or another type of cancer (like endometrial or breast cancer) or is a healthy volunteer willing to donate blood. Participants will provide a small blood sample, which will be used for research purposes. If you decide to take part, you will be contributing to important research that could help improve early diagnosis and treatment for ovarian cancer in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Blood plasma (1ml) from patients with ovarian cancer or borderline ovarian tumors, or other cancer tumors (endometrial, lymphoma, breast, malignant melanoma, sarcoma)
• • Blood plasma (1 ml) from healthy volunteer controls
• • Signed informed consent by cancer patients for use of biobank blood samples in research
• • Signed informed consent by healthy blood donors for use in research
• Exclusion Criteria:
• • \< 18 years (both for cancer patients and healthy blood donors)
• • Man (healthy blood donors)
• • \>70 years (healthy blood donors)

Trial Officials